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Abstract: Background: Cardiac resynchronization therapy (CRT) in chronic heart failure has been shown to improve mortality and morbidity.
However, comprehensive data are not available as concerns how circulating biomarkers reflecting different organ functions, such as serum uric
acid, blood urea nitrogen (BUN), albumin, cholesterol, or various liver enzymes, change over time as a consequence of CRT. The aim of this
prospective study was to overview these possible changes. Methods: A total of 20 routine laboratory parameters were measured in 122 control
subjects and in 129 patients with chronic heart failure before CRT, 6 months, and 2 years later. Results: The levels of serum uric acid [before:
432 (331–516) mmol/L, 6-month: 372 (304–452) mmol/L, 2-year: 340 (290–433) mmol/L; p < 0.001] and BUN [8.3 (6.4–11.5)
mmol/L, 8.0 (6.3–11.1) mmol/L, 6.8 (5.0–9.7) mmol/L; p < 0.001) reduced statistically significant. Total bilirubin underwent reduction [16
(11–23) μmol/L, 11 (7–14) μmol/L, 8 (7–13) μmol/L; p < 0.001], while albumin increased [45 (43–48) g/L, 46 (44–48) g/L, 46 (43–48)
g/L; p = 0.04]. Cholesterol concentrations elevated [4.3 (3.6–5.0) mmol/L, 4.5 (3.8–5.1) mmol/L, 4.6 (3.8–5.4) mmol/L; p < 0.001] and
glucose decreased [6.2 (5.6–7.2) mmol/L, 5.9 (5.1–6.7) mmol/L, 5.7 (5.1–6.8) mmol/L; p < 0.001]. Conclusions: CRT influences the levels
of routinely used biomarkers suggesting improvements in renal function, liver capacity, and metabolic changes. These changes could mirror the
multiorgan improvement after CRT.
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Introduction
Chronic heart failure affects multiple organs other than
the heart itself and should not be considered only as a
reduction in pump function. It activates the immune
system and induces global metabolic disturbances,
which can be traced by means of various laboratory
tests [1–3]. The inflammatory manifestations can be
followed via the elevated C-reactive protein (CRP)
levels, while the volume dysregulation leads to
increases in the N-terminal of the prohormone brain
natriuretic peptide (NT-proBNP) [4, 5]. A renal
dysfunction is characterized by changes in creatinine,
blood urea nitrogen (BUN), and uric acid levels,
liver and gastrointestinal malfunctions by elevated
liver enzymes and bilirubin, and decreased albumin
levels [6–11]. Metabolic changes result in hyperglyce-
mia and hypocholesterinemia [12, 13].
Cardiac resynchronization therapy (CRT) is an effec-
tive method in chronic heart failure accompanied by
ventricular dyssynchrony [14]. CRT has been shown to
have anti-inflammatory effects with a decreased volume
overload and an improved renal function [15–17]. Given
these systemic effects, it is surprising that comprehensive
data are not available as concerns how circulating bio-
markers associated with organ functions, such as serum
uric acid, BUN, albumin, cholesterol, or various liver
enzymes, are affected by CRT as a function of time.
The aim of this prospective study was to overview these
changes. We hypothesized that CRT is associated with
systemic biochemical changes that correlate with echo-
cardiographic improvement.
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Materials and Methods
Study population and study design
This prospective single-center observational follow-up
study was designed to evaluate the prognostic impact of
routinely used and novel biomarkers on the outcome
of chronic heart failure patients with CRT. We previously
described the role of blood count in CRT [18, 19]. This
analysis focuses on the changes of routine laboratory
parameters over time in the same population.
A cohort of 141 previously diagnosed and medically
treated patients with chronic heart failure [New York
Heart Association (NYHA) classes II–IV] with wide
QRS in the ECG (>120 ms) and a severely reduced
left ventricular ejection fraction (LVEF; <35%) were
referred to our center between September 2009 and
December 2010 for CRT implantation, according to
the current guidelines [20]. The exclusion criteria
included autoimmune diseases, hematologic diseases,
acute or chronic inflammatory diseases, and malignan-
cies. Four patients were excluded on this basis. The
CRT involved the implantation of a left ventricular lead
into the side branch of the coronary sinus, a right
ventricular lead in a septal position, and a right atrial
where appropriate.
Routine laboratory tests, physical examinations, and
ECG and echocardiographic measurements were car-
ried out before, 6 months, and 2 years after CRT
implantation. Echocardiographic measurements were
performed using the Philips iE33 system to calculate
the LVEF with Simpson’s method and left ventricular
volumes with the Teichholz method.
In the final analysis, 129 patients with chronic heart
failure were included with complete baseline laboratory
and echocardiographic data. Up to a median follow-up
time of 1,796 [922–2,023] days, a total of 46 patients
(36%) had died.
We also analyzed the data on 122 age [67 (61–73)
years], gender [82% male], and BMI [27 (24–30)
kg/m2]-matched healthy [QRS: 110 (93–125) ms;
LVEF: 67% (58–76)] control subjects, who participated
in the voluntary Budakalász Study at our clinic [21]. The
control group served to demonstrate the baseline labora-
tory alterations in the patients with chronic heart failure.
Prior to the enrollment, the local ethical committee at
the Semmelweis University had approved the protocol,
which was in accordance with the Helsinki Declaration,
and all of the subjects provided their written informed
consent.
The authors of this manuscript have certified that they
comply with the principles of ethical publishing in Inter-
ventional Medicine & Applied Science: Szél Á, Merkely
B, Hüttl K, Gál J, Nemes B, Komo´csi A: Statement on
ethical publishing and scientific authorship. IMAS 2,
101–102 (2010).
Laboratory measurements
Serum samples for routine laboratory measurements
at baseline, and at 6 months and 2 years after implantation
were collected and analyzed with the Cobas Integra
400 Plus® (Mannheim, Germany) clinical chemistry sys-
tem using absorbance photometric and turbidimetric
techniques. The following Roche Diagnostics (Man-
nheim, Germany) reagents were used: creatine kinase
(CK); creatine kinase MB isoenzyme (CKMB); creati-
nine; uric acid; BUN; CRP; glutamic oxaloacetic trans-
aminase (GOT); glutamic pyruvate transaminase (GPT);
gamma-glutamyl transferase (GGT); alkaline phosphatase
(ALP); lactate dehydrogenase (LDH); total bilirubin;
total protein; albumin; cholesterol; triglyceride; high-
density lipoprotein (HDL); low-density lipoprotein
(LDL); and glucose.
Aliquots for NT-proBNP were processed within 2 h of
sampling and were stored frozen at −80 °C until the
measurements. NT-proBNP levels weremeasured through
electrochemiluminescence with a Cobas e 411® analyzer
(Mannheim, Germany) using Roche Elecsys NT-proBNP
II kits (Cat. no.: 04842464190, Mannheim, Germany).
Table I Baseline parameters of the patients with chronic heart
failure
Age (years) 67 (60–73)
Male gender 105 (81)
Body mass index (kg/m2) 27 (24–30)
Ischemic etiology 74 (57)
Left bundle branch block 107 (82)
CRT-D 21 (16)
Optimal lead position 94 (72)
QRS (ms) 160 (150–180)
LVEF (%) 27 (23–33)
LVESV (mL) 210 (154–268)
LVEDV (mL) 303 (242–351)
NYHA III–IV 111 (86)
Hypertension 71 (55)
Diabetes mellitus 47 (36)
Angiotensin convertase inhibitor 123 (95)
Beta-blocker 115 (89)
Mineralocorticoid receptor inhibitor 92 (71)
Loop diuretics 101 (78)
Data are expressed as medians with interquartile ranges for continuous
variables and as event numbers with percentages for categorical vari-
ables. CRT-D= cardiac resynchronization therapy with an implantable
cardioverter defibrillator; LVEF= left ventricular ejection fraction;
LVESV= left ventricular end systolic volume; LVEDV= left ventricular
end diastolic volume; NYHA III–IV=New York Heart Association
classification III–IV. N= 129
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Statistical analysis
The data presented in this analysis deviated from normal
distribution (tested by the Shapiro–Wilk test), and the
data are therefore expressed as medians with interquartile
ranges (25th percentile to 75th percentile), or as percen-
tages with event numbers. A two-tailed p value of <0.05
was considered statistically significant in all cases. The
statistical analysis was carried out using GraphPad Prism
6.03 (GraphPad Software Inc., USA) software.
The Mann–Whitney test was used for independent
group comparisons. Dependent groups were assessed by
the Friedman test with Dunn post-hoc analysis. The
Spearman correlation was calculated.
Results
Baseline characteristics
The baseline characteristics of the 129 patients are displayed
in Table I. The majority of the patients were male (81%),
had ischemic etiology (57%) and a poor functional status
(NYHA III–IV: 86%), and were on optimal medication.
Their ECGs displayed a wideQRS [160 (150–180)ms] and
left bundle branch block morphology in 83% of the cases.
Echocardiographic changes
The CRT led to the LVEF being increased statistically
significant after 6 months [27% (23–33) vs. 37% (31–41),
p< 0.001], while the left ventricular end systolic volume
(LVESV) [210 (153–267) mL vs. 167 (111–234) mL,
p< 0.001] and left ventricular end diastolic volume
(LVEDV) [303 (242–351) mL vs. 259 (202–315) mL,
p< 0.001] were decreased. No further significant improve-
ment was seen at the 2-year follow-up in the LVEF
[42% (32–48)mL, p= 0.05], LVESV [160 (109–212)mL,
p= 0.57], and LVEDV [242 (195–305) mL, p= 0.60].
However, the improvement still persisted (baseline vs.
2 years, p< 0.001).
Changes in cardiac biomarkers
Figure 1 demonstrates the changes in cardiac laboratory
parameters. Compared with the healthy controls, the
Fig. 1. Changes in cardiovascular biomarkers. The data are expressed as medians with interquartile ranges (IQR). TheMann–Whitney test was
used for the comparison of the healthy control group (striated column) with the patients with chronic heart failure (blank columns).
The changes in the cardiovascular biomarkers of the patients with heart failure after cardiac resynchronization therapy were assessed
using the Friedman test with Dunn post-hoc analysis (C= control level, B = baseline level, 6= 6-month level, and 2 = 2-year level). NT-
proBNP =N-terminal of the prohormone brain natriuretic peptide; CK = creatine kinase; CKMB = creatine kinase MB isoenzyme;
LDH= lactate dehydrogenase. N (control) = 122; n (baseline) = 129; n (6-month) = 105; n (2-year) = 83. *0.01 ≤ p < 0.05;
**0.001 ≤ p < 0.01; ***p < 0.001; ns = not significant
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patients with chronic heart failure presented with elevated
NT-proBNP, CKMB, and LDH (p< 0.001), but with a
decreased CK level (p< 0.001). Two years after CRT, the
NT-proBNP concentration was decreased and the CK
level was increased (p< 0.001), while the CKMB and
LDH levels remained statistically unchanged (p= 0.99
and p= 0.26, respectively).
The change in NT-proBNP after 6 months correlated
well with those in the LVEF (r=−0.26, p= 0.006),
LVESV (r= 0.37, p< 0.001), and LVEDV (r= 0.28,
p= 0.003). The change in NT-proBNP after 2 years also
correlated with those in the LVEF (r=−0.42, p< 0.001),
LVESV (r= 0.50, p< 0.001), and LVEDV (r= 0.55,
p< 0.001). Additionally, the change in CK after 2 years
correlated with those in the LVESV (r= 0.34, p= 0.009)
and LVEDV (r= 0.37, p= 0.004). No other statistically
significant correlations were observed (data not shown).
Changes in renal and inflammatory parameters
Figure 2 reflects the significant elevations in both renal
(creatinine, uric acid, and BUN) and inflammatory
(CRP and total protein) markers in the patients with
chronic heart failure before CRT (p< 0.001). The renal
improvement at 2 years following CRT was characterized
by decreases in creatinine (p= 0.03), uric acid (p< 0.001),
and BUN (p= 0.008). The anti-inflammatory potential
of the CRT was suggested by the reductions in CRP
(p= 0.03) and total protein (p< 0.001).
The change in the serum creatine level at 6 months
was associated with an LVESV improvement (r= 0.24,
p= 0.01), while the change in uric acid was followed by
an LVEF recovery (r=−0.17, p= 0.04). The change in the
BUN level at 2 years correlated with the ventricular reverse
remodeling (LVESV: r= 0.23, p= 0.06 and LVEDV:
r= 0.29, p= 0.02). The change in CRP at 2 years paralleled
the LVEF improvement (r=−0.22, p= 0.04).
Changes in hepatic markers
Figure 3 reveals that the baseline levels of liver enzymes
(GOT, GPT, and GGT) and total bilirubin were elevated
(p< 0.001), while those of ALP were not (p= 0.14), and
the level of albumin (p= 0.04) was reduced in the
patients with chronic heart failure. At 2 years after the
CRT, the levels of GOT, GPT, and GGT decreased
significantly (p< 0.001), that of ALP was unchanged
(p= 0.99) and that of albumin was increased (p= 0.006).
Fig. 2. Changes in renal and inflammatory parameters. The data are expressed as medians with interquartile ranges (IQR). The Mann–Whitney
test was used for the comparison of the healthy control group (striated column) with the patients with chronic heart failure (blank
columns). The changes in renal and inflammatory parameters of the patients with heart failure after cardiac resynchronization therapy
were assessed using the Friedman test with Dunn post-hoc analysis (C= control level, B= baseline level, 6= 6-month level, and 2= 2-year
level). BUN= blood urea nitrogen; CRP=C reactive protein; T. protein= total protein. N (control)= 122; n (baseline)= 129;
n (6-month)= 105; n (2-year)= 83. *0.01 ≤ p< 0.05; **0.001 ≤ p< 0.01; ***p< 0.001; ns= not significant
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Of the hepatic parameters, the GGT change at 2 years
correlated with the change in the LVEF (r=−0.32,
p= 0.005).
Changes in metabolic parameters
As regards the baseline metabolic parameters, the patients
had low levels of lipoproteins (cholesterol, triglyceride,
HDL, and LDL), but a high glucose concentration
(p< 0.001), as demonstrated in Fig. 4. Following implan-
tation, the levels of lipoproteins increased (p< 0.001),
while those of the glucose decreased over time
(p= 0.01).
The triglyceride changes correlated with reductions in
the left ventricular volumes at 2 years (LVESV: r=−0.22,
p= 0.06 and LVEDV: r=−0.33, p= 0.005).
Discussion
Synopsis of the key findings
We found that the patients with chronic heart failure who
presented for CRT displayed cardiac congestion, tissue
damage, signs of inflammatory activation, impaired renal
and liver functions, low lipoprotein levels, and a high
glucose concentration. CRT resulted in echocardio-
graphic reverse remodeling, which persisted up to 2 years,
with accompanying improvements in renal function, liver
capacity, and metabolic changes.
Possible mechanisms and explanations
The results of this study confirm previous findings
relating to the laboratory changes in chronic heart
failure and the effects of CRT. The systemic inflamma-
tion and oxidative stress result in hyperglycemia, while
the ongoing inflammation drives the elevations in CRP
and total protein [1–4, 13]. The lipoproteins buffer
the inflammatory cytokines and endotoxins, and the
chronic inflammation therefore decreases the choles-
terol level [12]. The release of catecholamines and
sympathetic activation lead to a volume overload and
redistribution [1–3]. The volume overload enhances
NT-proBNP production, dilates the ventricles, and
causes cardiac tissue damage and remodeling, resulting
in increased levels of CKMB and LDH [5]. As one of
the characteristic features of chronic heart failure is
Fig. 3. Changes in hepatic markers. The data are expressed as medians with interquartile ranges (IQR). The Mann–Whitney test was used for
comparison of the healthy control group (striated column) with the patients with chronic heart failure (blank columns). The changes in
gastrointestinal markers of the patients with heart failure after cardiac resynchronization therapy were assessed by using the Friedman
test with Dunn post-hoc analysis (C= control level, B= baseline level, 6= 6-month level, 2= 2-year level). GOT= glutamic oxaloacetic
transaminase; GPT= glutamic pyruvate transaminase; GGT= gamma-glutamyl transferase; ALP= alkaline phosphatase; T. bilirubin=
total bilirubin. N (control)= 122; n (baseline)= 129; n (6-month)= 105; n (2-year)= 83. *0.01 ≤ p< 0.05; **0.001 ≤ p< 0.01;
***p< 0.001; ns= not significant
Routine laboratory tests in CRT
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reduced mitochondrial energy production in both the
cardiac and the skeletal muscle, a creatine phosphate
deficit develops with low CK activity and a con-
sequently reduced serum level [22]. On the other
hand, the volume redistribution decreases the renal
and gastrointestinal blood flows [23]. The consequent
liver dysfunction is reflected by elevated levels of liver
enzymes and total bilirubin, and decreased albumin
production, while the renal dysfunction is character-
ized by increases in the levels of serum creatinine, uric
acid, and BUN [6–8, 10, 11, 23, 24].
This was the first study that demonstrates how CRT
affects these routinely used biomarkers and the correlations
between the echocardiographic and laboratory changes.
CRT exerts reverse remodeling and improves the cardiac
function [25]. As the cardiac output increases, the volume
overload and redistribution decrease [26]. The release of
NT-proBNP lessens, while the level of CK increases, and
those of CKMB and LDH remain elevated, because
reverse remodeling is an active process with tissue
regeneration and a functional mitochondrial improvement
[26–28]. The volume distribution improves, and the
renal blood flow and filtration are restored, and conse-
quently, the excretion of creatinine, uric acid, and BUN is
enhanced and the serum levels decrease [15, 16]. The
better gastrointestinal circulation is mirrored by the
decreases in liver enzymes and total bilirubin and the
restored albumin production. The inflammatory processes
resolve, the levels of CRP and total protein decrease, and
the lipoproteins undergo a process of unbinding and their
levels are elevated [29].
Strengths and limitations
The main strength of this study is the overview of
routinely used biomarker changes in CRT, with the use
of a matched healthy control group. A possible limitation
could be the relatively small sample size. This analysis
should be considered as hypothesis generating and pre-
liminary, and larger trials are needed to confirm our
results.
Conclusions
This study has revealed how serum biomarkers can mirror
the multiorgan improvement after CRT. We found
that patients with chronic heart failure presenting for
CRT exhibited cardiac congestion, tissue damage and
Fig. 4. Changes in metabolic parameters. The data are expressed as medians with interquartile ranges (IQR). The Mann–Whitney test was used
for comparison of the healthy control group (striated column) with the patients with chronic heart failure (blank columns). The changes
in metabolic parameters of the patients with heart failure after cardiac resynchronization therapy were assessed by using the Friedman test
with Dunn post-hoc analysis (C= control level, B= baseline level, 6= 6-month level, 2= 2-year level). TG= triglyceride; HDL= high-
density lipoprotein; LDL= low-density lipoprotein.N (control)= 122; n (baseline)= 129; n (6-month)= 105; n (2-year)= 83. *0.01 ≤
p< 0.05; ***p< 0.001; ns= not significant
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steady-state inflammation, impaired renal and liver func-
tions, low lipoprotein levels, and a high glucose concen-
tration. CRT resulted in echocardiographic reverse
remodeling, which persisted up to 2 years. These changes
were followed by improvements in the renal function, the
liver capacity, and metabolism.
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